J L Halperin
Overview
Explore the profile of J L Halperin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldenberg N, Abshire T, Blatchford P, Fenton L, Halperin J, Hiatt W, et al.
J Thromb Haemost
. 2015 Jun;
13(9):1597-605.
PMID: 26118944
Background: Randomized controlled trials (RCTs) on pediatric venous thromboembolism (VTE) treatment have been challenged by unsubstantiated design assumptions and/or poor accrual. Pilot/feasibility (P/F) studies are critical to future RCT success....
2.
Lip G, Halperin J, Petersen P, Rodgers G, Pall D, Renfurm R
J Thromb Haemost
. 2015 Jun;
13(8):1405-13.
PMID: 26052866
Background: Darexaban (YM150) is a novel oral anticoagulant that directly inhibits factor Xa. Objectives: To investigate the optimal daily dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF)....
3.
Diener H, Halperin J, Fox K, Hankey G
Int J Clin Pract
. 2015 Apr;
69(7):743-56.
PMID: 25854636
Background: Atrial fibrillation (AF), the most common cardiac arrhythmia, is a major risk factor for stroke. Rivaroxaban, an oral factor Xa inhibitor, is approved for the prevention of stroke in...
4.
Girgis I, Patel M, Peters G, Moore K, Mahaffey K, Nessel C, et al.
J Clin Pharmacol
. 2014 Mar;
54(8):917-27.
PMID: 24668660
Two once-daily rivaroxaban dosing regimens were compared with warfarin for stroke prevention in patients with non-valvular atrial fibrillation in ROCKET AF: 20 mg for patients with normal/mildly impaired renal function...
5.
Kittelson J, Spyropoulos A, Halperin J, Kessler C, Schulman S, Steg G, et al.
J Thromb Haemost
. 2013 Jun;
11(8):1443-8.
PMID: 23773172
Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate...
6.
Spyropoulos A, Goldenberg N, Kessler C, Kittelson J, Schulman S, Turpie A, et al.
J Thromb Haemost
. 2012 Sep;
10(12):2621-4.
PMID: 23006126
No abstract available.
7.
Lubitz S, Scott S, Rothlauf E, Agarwal A, Peter I, Doheny D, et al.
J Thromb Haemost
. 2010 Feb;
8(5):1018-26.
PMID: 20128861
Summary Background: Gene-based warfarin dosing algorithms have largely been developed in homogeneous populations, and their generalizability has not been established. Objectives: We sought to assess the performance of published algorithms...
8.
Buller H, Halperin J, Bounameaux H, Prins M
J Thromb Haemost
. 2007 Nov;
6(2):227-9.
PMID: 18034770
No abstract available.
9.
Ryden L, Asinger R, Cannom D, Crijns H, Frye R, Halperin J, et al.
Circulation
. 2001 Oct;
104(17):2118-50.
PMID: 11673357
No abstract available.
10.
Fuster V, Ryden L, Asinger R, Cannom D, Crijns H, Frye R, et al.
Eur Heart J
. 2001 Oct;
22(20):1852-923.
PMID: 11601835
No abstract available.